The Relationship Between The Expression Of Scinderin,E-Cadherin And The Efficacy Of Neoadjuvant Chemotherapy In Breast Cancer

Background and Objective:Affected by multiple factors,the incidence of breast cancer in women increased day by day,Breast cancer have become the top killer of women in some countries and regions.Studies have shown that the occurrence and development of breast cancer is a complex cascade reaction process involving multiple factors and carried out in stages and steps.As scientists further study the pathogenesis of breast cancer,The Neoadjuvant chemotherapy(NACT)is an increasingly promoted method of an accepted and effective treatment of locally advanced and inflammatory breast cancer.Parts of the patients can achieve a pathologic complete response(pCR)to neoadjuvant therapy.The most important meaning for pathologic complete response is to predicate a good long-term outcomes.However,70-90% of the patients can not achieve pCR with neoadjuvant chemotherapy.In addition,the overall clinical response rate of neoadjuvant chemotherapy is about 65-90%.Therefore,it is urgent to select new sensitive biomarkers to determine which populations can benefit from neoadjuvant chemotherapy for breast cancer.There is limited research on the expression of scinderin and epithelial cadherin(E-Cad)in relationship to the efficacy of neoadjuvant chemotherapy and the results are quite controversial.Our study shed lights on this issue by analyzing data of Scinderin and E-cadherin before and after neoadjuvant chemotherapy for 56 patients who also underwent mastectomy.The objectives of our study are as follows:(1)To analyze the expression level of Scinderin and E-cadherin in breast cancer to evaluate the effects of treatment before and after neoadjuvant chemotherapy.(2)To verify the relationship between the expression of Scinderin,E-cadherin in breast cancer and the efficacy of neoadjuvant chemotherapy.Thus,to further verify if Scinderin and E-cadherin can be used as a predictor of treatment efficacy for neoadjuvant chemotherapy for breast cancer。(3)To testify the relationship of Scinderin and E-cadherin by means of immunohistochemistry。 Methods:There are 56 patients diagnosed as breast cancer at II-III stage(category by TNM from AJCC)by fine needle biopsy(FNA)in JiangXi PingXiang People?s hospital from 2016.1-2018.6.All cases were treated with uniform chemotherapy regimens “EC”X4cycles and then underwent radical surgery.Detect the expression of Scinderin and E-cadherin in specimens before and after NACT by SP IHC.Analyze the change of the expression level of Scinderin and E-cadherin before and after NACT,analyze the relationship between the expression of Scinderin and E-cadherin in breast cancer and the efficacy of neoadjuvant chemotherapy,testify the correlation between the expression level of Scinderin and E-cadherin and the patients clinical traits.Results:1.Among the 56 patients who have accepted 4 cycles of EC neoadjuvant chemotherapy,the sensitivity to the chemotherapy is at the rate of 67.9%(38/56)。2.After NACT the expression of Scinderin and E-cadherin is significantly decreased(P<0.05).3.The expression of SCIN and E-CAD is different by group before and after NACT.(1)The average of the IOD in SCIN and E-CAD significantly decreased after NACT in the group which is sensitive to the chemotherapy(P<0.05).(2)The average of the IOD in SCIN has a decreased after NACT in the group which is non-sensitive to the chemotherapy((P<0.05).and the average of the IOD in E-CAD is the same after NACT in the group which is non-sensitive to the chemotherapy.(3)There is no correlation of the expression of the SCIN and E-CAD between the sensitive and non-sensitive group before NACT.After NACT,the expression of SCIN and E-cad have a negatively correlation between the sensitive and non-sensitive group.4.The decline level of SCIN and E-CAD in the sensitive and non-sensitive group before and after NACT.(1)The average decline level of the SCIN expressed before and after NACT is 11.527±6.55 in sensitive group.The average decline level of the SCIN expressed before and after NACT is 6.307±10.666 in non-sensitive group(P<0.05).(2)The average decline level of the E-CAD expressed before and after NACT is 7.146±9.839 in sensitive group.The average decline level of the SCIN expressed before and after NACT is 2.561±12.448 in non-sensitive group(P<0.05).(3)Scinderin average integral optical density decline value(S drop for short)predicted the area under sensitive ROC was 0.731,while E-cadherin average integral optical density decline value(E drop for short)predicted the area under sensitive ROC was 0.765,both > and 0.7,indicating good predictive value.The area under the curve was statistically significant.(S drop = 0.006;E drop=0.006.)(4)According to the principle of maximum Jordan index,the cutoff values(marked in red)of S drop and E drop in predicting curative effect were defined.S 8.31,indicating sensitivity(effective),E 7.59 indicating sensitivity(effective).5.Relationship between expression of Scinderin and E-cadherin in breast cancer tissues and clinicopathological characteristics:(1)Scinderin expression was associated with age,TNM stage,and lymph node metastasis(P<0.05).Young breast cancer patients had earlier clinical stages,and postoperative pathology indicated that Scinderin decreased more significantly in patients without lymph node metastasis after NACT.There was no significant correlation with menstrual status,tissue grading and molecular typing.(2)There was no significant correlation between e-cadherin expression and age,menstrual status,tumor size,histological grade,clinical stage,lymph node metastasis and molecular typing.6.Correlation analysis of Scinderin expression and e-cadherin expression:(1)The expression of Scinderin and e-cadherin was weakly correlated or not correlated before chemotherapy(P > 0.05).(2)The expression of Scinderin and E-cadherin was positively correlated after chemotherapy(P<0.05).Conclusions:1.Breast cancer neoadjuvant chemotherapy(EC)is an effective treatment for breast cancer.2.Neoadjuvant chemotherapy can reduce the positive expression of Scinderin and E-cadherin in cancer tissues.The expression values of Scinderin and E-cadherin after chemotherapy were negatively correlated with the efficacy of chemotherapy,and the lower the expression values of SCIN and E-cad after chemotherapy,the better the efficacy of chemotherapy.3.The decreased values of Scinderin and e-cadherin after neoadjuvant chemotherapy were significantly correlated with the efficacy of chemotherapy.The more significant the decrease of Scinderin and e-cadherin after NACT,the better the effect of NACT.4.Scin plays a synergistic role with e-cad in the occurrence and development of breast cancer.Scinderin combined with e-cadherin can be used as a predictor of the efficacy of neoadjuvant chemotherapy for breast cancer.